These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9075853)

  • 1. Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group.
    Pescovitz MD; Barone G; Choc MG; Hricik DE; Hwang DS; Jin JH; Klein JB; Marsh CL; Min DI; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1997 Mar; 63(5):778-80. PubMed ID: 9075853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group.
    Cole E; Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffrey J; Russell D; Stiller C; Muirhead N; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P; Tan A; Hendricks L
    Transplantation; 1998 Feb; 65(4):505-10. PubMed ID: 9500624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group.
    Barone G; Chang CT; Choc MG; Klein JB; Marsh CL; Meligeni JA; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1996 Mar; 61(6):875-80. PubMed ID: 8623152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation.
    Eisen HJ; Hobbs RE; Davis SF; Laufer G; Mancini DM; Renlund DG; Valantine H; Ventura H; Vachiery JL; Bourge RC; Canver CC; Carrier M; Costanzo MR; Copeland J; Dureau G; Frazier OH; Dorent R; Hauptman PJ; Kells C; Master R; Michaud JL; Paradis I; Smith A; Vanhaecke J; Mueller EA
    Transplantation; 1999 Sep; 68(5):663-71. PubMed ID: 10507486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
    Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
    Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
    Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
    Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantation.
    Eisen HJ; Hobbs RE; Davis SF; Carrier M; Mancini DM; Smith A; Valantine H; Ventura H; Mehra M; Vachiery JL; Rayburn BK; Canver CC; Laufer G; Costanzo MR; Copeland J; Dureau G; Frazier OH; Dorent R; Hauptman PJ; Kells C; Masters R; Michaud JL; Paradis I; Renlund DG; Vanhaecke J; Mellein B; Mueller EA
    Transplantation; 2001 Jan; 71(1):70-8. PubMed ID: 11211198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1996 Mar; 61(6):968-70. PubMed ID: 8623168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
    Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA
    Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients.
    Dunn S; Cooney G; Sommerauer J; Lindsay C; McDiarmid S; Wong RL; Chang CT; Smith HT; Choc MG
    Transplantation; 1997 Jun; 63(12):1762-7. PubMed ID: 9210501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients.
    Briggs D; Dudley C; Pattison J; Pfeffer P; Salmela K; Rowe P; Tydén G;
    Transplantation; 2003 Jun; 75(12):2058-63. PubMed ID: 12829912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.
    Levy G; Villamil F; Samuel D; Sanjuan F; Grazi GL; Wu Y; Marotta P; Boillot O; Muehlbacher F; Klintmalm G;
    Transplantation; 2004 Jun; 77(11):1632-8. PubMed ID: 15201658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group.
    Marsh CL
    Ther Drug Monit; 1999 Feb; 21(1):27-34. PubMed ID: 10051051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoral conversion from Sandimmune in maintenance renal transplant patients: an individualized approach.
    Curtis JJ; Lynn M; Jones PA
    J Am Soc Nephrol; 1998 Jul; 9(7):1293-300. PubMed ID: 9644641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.